Press Releases

WHITE PLAINS, NEW YORK, UNITED STATES, Febryary 11, 2025 — Retia Medical, an innovator in AI algorithms for patient monitoring and management, announced that it has entered into an agreement with Medtronic plc, a global leader in healthcare technology, to distribute the Argos Cardiac Output Monitor designed to provide healthcare professionals with highly accurate hemodynamic data to support the treatment of high-risk surgical and critically ill patients.

In the operating room (OR) and Intensive Care Unit (ICU), circulatory shock, often diagnosed as hypotension, is a primary cause of complications and requires intervention within 1 to 2 minutes to prevent damage to vital organs. Hemodynamic monitoring detects important changes in a patient’s hemodynamic status, enables clinicians to intervene earlier ensuring sufficient oxygen delivery and preserving end organ function. In addition, patients had 1 to 2-day shorter stays in the ICU when preemptive hemodynamic intervention was used.1,2

“Medtronic is the ideal partner for Retia Medical as we expand the reach of the Argos cardiac output monitor,” said Marc Zemel, chief executive officer of Retia Medical. “Their robust portfolio, strong customer relationships, and leadership in advancing acute care and monitoring technologies uniquely position them to deliver the benefits of our innovative solution to clinicians and patients in the U.S. We are excited to partner with Medtronic to set a new standard in hemodynamic monitoring.”

“Studies have shown that preemptive hemodynamic intervention can significantly reduce mortality and surgical complications,” said Frank Chan, president of the Acute Care & Monitoring business at Medtronic. “The Argos cardiac output monitor compliments our INVOS™ cerebral oximetry technology, to help provide clinicians with comprehensive insights into a patient’s status. By integrating this technology into our Acute Care & Monitoring portfolio, we are advancing our commitment to delivering actionable insights that enable clinicians to personalize care and improve outcomes for critically ill patients.”

The Argos cardiac output monitor offers a unique advanced algorithm called Multi-Beat Analysis (MBA®) that was developed at the Massachusetts Institute of Technology (MIT) and Michigan State University. Unlike other monitors that analyze only one beat at a time, the MBA algorithm analyzes multiple heartbeats from the blood pressure signal to model a patient’s vascular resistance directly. So, it provides accurate hemodynamic data on ten comprehensive parameters even during changes in vasomotor tone, low cardiac output, and arrhythmia.

The Argos cardiac output monitor leverages the patient’s existing arterial line using a single reusable cable to connect. This approach enables continuous and reliable monitoring, even during hemodynamic instability. The monitor requires no calibration, features an intuitive multi-touch screen interface, and can be fully operational in under one minute, with training completed in less than five minutes. In addition, there is no need for costly disposable accessories.

About Retia Medical

Headquartered in White Plains, NY, Retia Medical Systems, Inc. is a venture-backed developer and provider of advanced algorithms including AI-based approaches for patient monitoring and management. Retia’s mission is to provide accurate data and insights to aid surveillance, diagnosis and management of high-risk surgical and critically ill patients to improve outcomes. Retia Medical’s Argos Monitor, with its Multi-Beat Analysis (MBA®) algorithm, provides consistently accurate hemodynamic measurements for critically ill adult patients, enabling clinicians to make more informed, data-driven decisions to improve end-organ function. Additionally, the Argos system is unique in its class by not requiring costly disposables to monitor each patient. The Argos uses a single cable connection and takes less than 1 minute to start monitoring. Learn more at www.retiamedical.com and follow us on LinkedIn Retia Medical.

For more information on Medtronic (NYSE:MDT), visit www.Medtronic.com and follow Medtronic on LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contact:
Cathy Wilkes
Product Manager
cwilkes@retiamedical.com
+1 (717) 873-4336

References:

1. Hamilton MA, Cecconi M, Rhodes A. A systematic review and meta-analysis on the use of preemptive hemodynamic intervention to improve postoperative outcomes in moderate and high-risk surgical patients. Anesth Analg. 2011;112(6):1392-1402. doi:10.1213/ANE.0b013e3181eeaae5.
2. Giglio M, Dalfino L, Puntillo F, Brienza N. Hemodynamic goal-directed therapy and postoperative kidney injury: an updated meta-analysis with trial sequential analysis. Crit Care. 2019;23(1):232. Published 2019 Jun 26. doi:10.1186/s13054-019-2516-